Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats

Hirokazu Tsukahara, M. Hiraoka, C. Hori, I. Hata, T. Okada, F. Gejyo, M. Sudo

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To examine the effect of chronic administration of recombinant human erythropoietin (rHuEPO) on endogenous nitric oxide (NO) activity, we treated Sprague-Dawley rats with rHuEPO (100 IU kg-1 or 300 IU kg-1) or a corresponding vehicle for 2 weeks, administered subcutaneously on alternate days. Treatment elicited increases in haematocrit and systolic blood pressure in a dose-dependent fashion. Simultaneous administration of N(G)-nitro-L-arginine methyl ester (L-NAME, 20 mg dl-1 of drinking water), but not aminoguanidine (400 mg dl-1), induced a further significant rise in blood pressure. The effect of L-NAME was inhibited by a large dose of L-arginine (2.0 g dl-1). Polycythaemia and hypertension induced by chronic rHuEPO therapy were associated with increased urinary NO2 - and NO3 - (NOx-) excretion, while co-administration of L-NAME, but not aminoguanidine, reduced NOx- excretion. Our results indicate that chronic rHuEPO treatment has a significant presser effect, but induces a compensatory increase in the steady-state release of NO by constitutive NO synthase in normal rats. Such enhanced NO synthesis may act as a protective mechanism against the hypertensive effect of rHuEPO.

Original languageEnglish
Pages (from-to)487-493
Number of pages7
JournalScandinavian Journal of Clinical and Laboratory Investigation
Volume57
Issue number6
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Erythropoietin
NG-Nitroarginine Methyl Ester
Rats
Nitric Oxide
Blood pressure
Blood Pressure
Polycythemia
Hematocrit
Nitric Oxide Synthase
Drinking Water
Sprague Dawley Rats
Arginine
Hypertension
pimagedine
Therapeutics

Keywords

  • Endogenous nitric oxide activity
  • Hypertension
  • Nitric oxide synthase inhibitors
  • NO and NO
  • Recombinant human erythropoietin

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats. / Tsukahara, Hirokazu; Hiraoka, M.; Hori, C.; Hata, I.; Okada, T.; Gejyo, F.; Sudo, M.

In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 57, No. 6, 1997, p. 487-493.

Research output: Contribution to journalArticle

Tsukahara, Hirokazu ; Hiraoka, M. ; Hori, C. ; Hata, I. ; Okada, T. ; Gejyo, F. ; Sudo, M. / Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats. In: Scandinavian Journal of Clinical and Laboratory Investigation. 1997 ; Vol. 57, No. 6. pp. 487-493.
@article{bd37a68c9ef8406d96b700b821d29dcf,
title = "Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats",
abstract = "To examine the effect of chronic administration of recombinant human erythropoietin (rHuEPO) on endogenous nitric oxide (NO) activity, we treated Sprague-Dawley rats with rHuEPO (100 IU kg-1 or 300 IU kg-1) or a corresponding vehicle for 2 weeks, administered subcutaneously on alternate days. Treatment elicited increases in haematocrit and systolic blood pressure in a dose-dependent fashion. Simultaneous administration of N(G)-nitro-L-arginine methyl ester (L-NAME, 20 mg dl-1 of drinking water), but not aminoguanidine (400 mg dl-1), induced a further significant rise in blood pressure. The effect of L-NAME was inhibited by a large dose of L-arginine (2.0 g dl-1). Polycythaemia and hypertension induced by chronic rHuEPO therapy were associated with increased urinary NO2 - and NO3 - (NOx-) excretion, while co-administration of L-NAME, but not aminoguanidine, reduced NOx- excretion. Our results indicate that chronic rHuEPO treatment has a significant presser effect, but induces a compensatory increase in the steady-state release of NO by constitutive NO synthase in normal rats. Such enhanced NO synthesis may act as a protective mechanism against the hypertensive effect of rHuEPO.",
keywords = "Endogenous nitric oxide activity, Hypertension, Nitric oxide synthase inhibitors, NO and NO, Recombinant human erythropoietin",
author = "Hirokazu Tsukahara and M. Hiraoka and C. Hori and I. Hata and T. Okada and F. Gejyo and M. Sudo",
year = "1997",
language = "English",
volume = "57",
pages = "487--493",
journal = "Scandinavian Journal of Clinical and Laboratory Investigation",
issn = "0036-5513",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats

AU - Tsukahara, Hirokazu

AU - Hiraoka, M.

AU - Hori, C.

AU - Hata, I.

AU - Okada, T.

AU - Gejyo, F.

AU - Sudo, M.

PY - 1997

Y1 - 1997

N2 - To examine the effect of chronic administration of recombinant human erythropoietin (rHuEPO) on endogenous nitric oxide (NO) activity, we treated Sprague-Dawley rats with rHuEPO (100 IU kg-1 or 300 IU kg-1) or a corresponding vehicle for 2 weeks, administered subcutaneously on alternate days. Treatment elicited increases in haematocrit and systolic blood pressure in a dose-dependent fashion. Simultaneous administration of N(G)-nitro-L-arginine methyl ester (L-NAME, 20 mg dl-1 of drinking water), but not aminoguanidine (400 mg dl-1), induced a further significant rise in blood pressure. The effect of L-NAME was inhibited by a large dose of L-arginine (2.0 g dl-1). Polycythaemia and hypertension induced by chronic rHuEPO therapy were associated with increased urinary NO2 - and NO3 - (NOx-) excretion, while co-administration of L-NAME, but not aminoguanidine, reduced NOx- excretion. Our results indicate that chronic rHuEPO treatment has a significant presser effect, but induces a compensatory increase in the steady-state release of NO by constitutive NO synthase in normal rats. Such enhanced NO synthesis may act as a protective mechanism against the hypertensive effect of rHuEPO.

AB - To examine the effect of chronic administration of recombinant human erythropoietin (rHuEPO) on endogenous nitric oxide (NO) activity, we treated Sprague-Dawley rats with rHuEPO (100 IU kg-1 or 300 IU kg-1) or a corresponding vehicle for 2 weeks, administered subcutaneously on alternate days. Treatment elicited increases in haematocrit and systolic blood pressure in a dose-dependent fashion. Simultaneous administration of N(G)-nitro-L-arginine methyl ester (L-NAME, 20 mg dl-1 of drinking water), but not aminoguanidine (400 mg dl-1), induced a further significant rise in blood pressure. The effect of L-NAME was inhibited by a large dose of L-arginine (2.0 g dl-1). Polycythaemia and hypertension induced by chronic rHuEPO therapy were associated with increased urinary NO2 - and NO3 - (NOx-) excretion, while co-administration of L-NAME, but not aminoguanidine, reduced NOx- excretion. Our results indicate that chronic rHuEPO treatment has a significant presser effect, but induces a compensatory increase in the steady-state release of NO by constitutive NO synthase in normal rats. Such enhanced NO synthesis may act as a protective mechanism against the hypertensive effect of rHuEPO.

KW - Endogenous nitric oxide activity

KW - Hypertension

KW - Nitric oxide synthase inhibitors

KW - NO and NO

KW - Recombinant human erythropoietin

UR - http://www.scopus.com/inward/record.url?scp=0030760293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030760293&partnerID=8YFLogxK

M3 - Article

C2 - 9350067

AN - SCOPUS:0030760293

VL - 57

SP - 487

EP - 493

JO - Scandinavian Journal of Clinical and Laboratory Investigation

JF - Scandinavian Journal of Clinical and Laboratory Investigation

SN - 0036-5513

IS - 6

ER -